A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies
dc.contributor.author | Sharp, A. | |
dc.contributor.author | Williams, A. | |
dc.contributor.author | Blagden, S. P. | |
dc.contributor.author | Plummer, E. R. | |
dc.contributor.author | Hochhauser, D. | |
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Pacey, S. | |
dc.contributor.author | Evans, T. R. J. | |
dc.contributor.author | Whelan, S. | |
dc.contributor.author | Nandakumar, S. | |
dc.contributor.author | Rogers, S. | |
dc.contributor.author | Jameson, K. L. | |
dc.contributor.author | Basile, F. G. | |
dc.contributor.author | De Bono, J. S. | |
dc.contributor.author | Arkenau, H. T. | |
dc.date.accessioned | 2022-11-30T10:21:31Z | |
dc.date.available | 2022-11-30T10:21:31Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Sharp A, Williams A, Blagden SP, Plummer ER, Hochhauser D, Krebs M, et al. A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304856. | en |
dc.identifier.doi | 10.1200/JCO.2022.40.16_suppl.TPS2691 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625827 | |
dc.title | A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton | en |
dc.identifier.journal | Journal of Clinical Oncology | en |
dc.description.note | en] |